Vet Oncologist Viewpoint
"Targeted therapies have a great deal to offer veterinary oncologists and animals. Right now in veterinary oncology we have one main targeted therapy, a drug call Palladia. It's a drug that I have a huge amount of experience with - we have been using it for 10-15 years or longer. It was originally approved for a particular type of cancer that's quite common in dogs called 'mast cell tumors', and it is effective in a subset of those.
What we have also found is that this targeted therapy is effective in many other types of cancers: thyroid cancer, bone cancer, anal sac adenocarcinoma, and others. Currently, there are a lot more targeted therapies available for people than for dogs, but I'm really excited to work on applying the whole host of targeted therapies that we have available in the human realm.
In people, it is often the standard of care, for instance if a person is diagnosed with lung cancer, for that lung cancer to be genomically analyzed, and the treatment based upon the genomic results. The results of treating based upon the genomic signature of the cancer has improved the treatment of lung cancer dramatically. I am unbelievably excited about taking this technology and replicating it in the veterinary space, so we can genomically analyze canine cancers, and match therapy based upon the genomic signature. The One Health Company can help us do that."
Founder The Veterinary Cancer Center & Animal Cancer Foundation; One Health Chief Veterinary Officer
FidoCure is a targeted treatment approach (aka precision medicine). Unlike traditional treatments that kill both healthy and unhealthy cells, the drugs your veterinarian will prescribe, utilizing our genetic tests will preferentially attack unhealthy cells. We help veterinarians match the right dog to the right drug.
Traditional Canine Cancer Treatment
One size fits all approach
Genetic information to tailor treatment
1. Cancer Research
The first revolution in cancer research has been understanding the disease. Starting in the 1970’s Bishop & Varmus (1989 Nobel Prize for the discovery of Oncogene), demonstrated that cancer is a disease of genetic mutations for both animals and humans. Moreover, a cancer’s genetic mutational profile is more important than its tissue of origin for predicting its response to therapy.
2. Advanced Diagnostics
Relatedly, access to faster and cheaper DNA and RNA sequencing means that an individual tumor’s genetics could be sequenced in a medically-relevant time-frame, and those data could be used to inform treatment.
3. About Targeted Therapies
With a better understanding of cancer, scientists started creating a next generation of drugs that produced superior patient outcomes. This new class of drugs slows cancer growth by inhibiting specific cancer mutations. With sequencing information and precision therapies, cancer patients are living longer, with fewer side effects (when compared to cytotoxic chemotherapy).
4. The One Health Company
We are the first and only company offering precision medicine for canine cancer, leading the future of canine cancer care.
Targeted Drug Therapy*
(From National Cancer Institute)
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules (“molecular targets”) that are involved in the growth, progression, and spread of cancer. Targeted cancer therapies are sometimes called “molecularly targeted drugs,” “molecularly targeted therapies,” “precision medicines,” or similar names. Targeted therapies differ from standard chemotherapy in several ways:
Targeted therapies can act on specific molecular targets that are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells.
Targeted therapies are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies were identified because they kill cells.
Targeted therapies can have tumor specific cytotoxic and cytostatic effects (that is, they can be lethal or simply halt tumor cell proliferation), whereas standard chemotherapy agents are cytotoxic (that is, they kill tumor cells and dividing normal cells alike).
(*Targeted Cancer Therapies was originally published by the National Cancer Institute.)